Acute Otitis Externa Clinical Trial
Official title:
A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution Compared to DF289 Otic Solution and to DF277 Otic Solution in the Treatment of Acute Otitis Externa (AOE)
Verified date | November 2020 |
Source | Salvat |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine if a combination of an antibiotic plus a corticosteroid is safe and effective in treating AOE
Status | Completed |
Enrollment | 493 |
Est. completion date | September 14, 2018 |
Est. primary completion date | August 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months and older |
Eligibility | Inclusion Criteria: - Uncomplicated AOE of less tan 21 days, defined as a total symptom score of at least 2 for otalgia, 2 for edema and 1 for otorrhea - Brighton Grading of II or III - Culture-based diagnosis of acute bacterial otitis externa - Willingness to refrain from swimming through end of the study Exclusion Criteria: - Previous episode of AOE within 4 weeks prior to enrollment, or 2 or more episodes of AOE within 6 months prior to the enrollment. - Tympanic membrane perforation - Any condition or situation likely to cause the patient to be unable or unwilling to comply with study treatment or attend all study visits - Any condition in the patient or parent/guardian that, in the judgment of the principal investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study |
Country | Name | City | State |
---|---|---|---|
Spain | Laboratorios SALVAT | Esplugues de Llobregat |
Lead Sponsor | Collaborator |
---|---|
Salvat |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Therapeutic Cure (Clinical + Microbiological Cure) | Therapeutic cure will be considered achieved if edema, otalgia and otorrhea are resolved with no further requirement of antimicrobial therapy and bacteriological response is Eradication or Presumed Eradication | End of Treatment (Day 8+2) | |
Secondary | Time to End of Pain | First day on which there is no use of analgesics, the pain score is zero and remains zero until end of study | From baseline to End of Study (Day 15+2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02918773 -
Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)
|
N/A | |
Not yet recruiting |
NCT04636957 -
A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)
|
Phase 3 | |
Completed |
NCT01447017 -
A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis
|
Phase 2 | |
Completed |
NCT01535599 -
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT02801370 -
Phase 3 Study of OTO-201 in Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT00750633 -
A Phase III Study of an Otic Formulation in Acute Otitis Externa
|
Phase 3 | |
Terminated |
NCT00945802 -
FST-201 In The Treatment of Acute Otitis Externa
|
Phase 3 | |
Recruiting |
NCT01584271 -
Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)
|
Phase 2 | |
Completed |
NCT02216071 -
Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT00961675 -
FST-201 in the Treatment of Acute Otitis Externa
|
Phase 3 | |
Completed |
NCT01535560 -
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
|
Phase 3 |